in early-stage choroidal melanoma. Bel-sar is from a novel class of virus-like drug conjugate therapies that Boston, Massachusetts-based Aura is developing for various oncology indications.

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

After hours: March 21 at 4:54:30 PM EDT Loading Chart for AURA ...